Want to join the conversation?
$ABBV said Imbruvica is tracking in line to slightly ahead of its expectations, following its approval for first-line use in chronic lymphocytic leukemia. Imbruvica has achieved the number one market share position in all approved disease indications in second-line and second-line plus treatment.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.